



1 9 September 2016
2 EMA/CHMP/ICH/453276/2016
3 Committee for Human Medicinal Products

4 **ICH guideline E17 on general principles for planning and**
5 **design of multi-regional clinical trials**
6 **Step 2b**

Transmission to CHMP	21 July 2016
Transmission to interested parties	28 July 2016
Deadline for comments	28 January 2017

7
8

Comments should be provided using this [template](#). The completed comments form should be sent to ich@ema.europa.eu

9
10



11 General principles for planning and design of multi-
12 regional clinical trials E17

13 **Table of contents**

14	1. Introduction	3
15	1.1. Objectives of the guideline	3
16	1.2. Background	3
17	1.3. Scope of the guideline.....	3
18	1.4. Basic principles	4
19	2. General recommendations in the planning and design of MRCTs	5
20	2.1. Strategy-related issues	5
21	2.1.1. The value of MRCTs in drug development	5
22	2.1.2. Basic requirements and key considerations	6
23	2.1.3. Scientific consultation meetings with regulatory authorities.....	7
24	2.2. Clinical trial design and protocol-related issues	7
25	2.2.1. Pre-consideration of regional variability and its potential impact on efficacy and safety	
26	7
27	2.2.2. Subject selection	8
28	2.2.3. Selection of doses for use in confirmatory MRCTs	8
29	2.2.4. Choice of endpoints	9
30	2.2.5. Estimation of an overall sample size and allocation to regions	10
31	2.2.6. Collecting and handling of efficacy and safety information	13
32	2.2.7. Statistical analysis planning to address Specific features of MRCTs	13
33	2.2.8. Selection of comparators	15
34	2.2.9. Handling concomitant medications.....	16
35	3. Glossary	17
36		
37		

38 **1. Introduction**

39 **1.1. Objectives of the guideline**

40 With the increasing globalisation of drug development, it has become important that data from multi-
41 regional clinical trials (MRCTs) can be accepted by regulatory authorities across regions and countries
42 as the primary source of evidence to support marketing approval of drugs (medicinal products). The
43 purpose of this guideline is to describe general principles for the planning and design of MRCTs with
44 the aim of increasing the acceptability of MRCTs in global regulatory submissions. The guideline
45 addresses some strategic programme issues as well as those issues that are specific to the planning
46 and design of confirmatory MRCTs and should be used together with other ICH guidelines, including
47 E2, E3, E4, E5, E6, E8, E9, E10 and E18.

48 **1.2. Background**

49 Globalisation of drug development has increased the use of MRCTs for regulatory submissions in ICH
50 regions as well as in non-ICH regions. Currently, it may be challenging both operationally and
51 scientifically to conduct a drug development programme globally, in part due to distinct and sometimes
52 conflicting requirements from regulatory authorities. At the same time, regulatory authorities face
53 increasing challenges in evaluating data from MRCTs for drug approval. Data from MRCTs are often
54 submitted to multiple regulatory authorities without a previous harmonised regulatory view on the
55 study plan. There are currently no ICH guidelines that deal with the planning and design of MRCTs,
56 although the ICH E5 Guideline covers issues relating to the bridging of results from one region to
57 another. The present guideline describes the principles for planning and design of MRCTs, in order to
58 increase the acceptability of MRCTs by multiple regulatory authorities.

59 MRCTs conducted according to the present guideline will allow investigation of treatment effects in
60 overall populations with multiple ethnic factors (intrinsic and extrinsic factors as described in the ICH
61 E5 guideline) as well as investigating consistency in treatment effects across populations. Hence, using
62 the present guideline for planning MRCTs may facilitate a more efficient drug development and provide
63 earlier access to medicines. In addition, MRCTs conducted according to the present guideline may
64 enhance scientific knowledge about how treatment effects vary across populations and ethnicities
65 under the umbrella of a single study protocol. This information is essential for simultaneous drug
66 development to treat a broad patient population.

67 **1.3. Scope of the guideline**

68 MRCT in the present guideline is defined as a clinical trial conducted in more than one region under a
69 single protocol. In this context, region may refer to a geographical region, country or regulatory region
70 (see also section 3. Glossary). The primary focus of this guideline is on MRCTs designed to provide
71 data that will be submitted to multiple regulatory authorities for drug approval (including approval of
72 additional indications, new formulations and new dosing regimens) and for studies conducted to satisfy
73 post-marketing requirements. Certain aspects of this guideline may be relevant to trials conducted
74 early in clinical development or in later phases. The present guideline mainly covers drugs, including
75 biological products, but principles described herein may be applicable to studies of other types of
76 treatments.

77 **1.4. Basic principles**

78 MRCTs are generally the preferred option for investigating a new drug for which regulatory submission
79 is planned in multiple regions. The underlying assumption of the conduct of MRCTs is that the
80 treatment effect is clinically meaningful and relevant to all regions being studied. This assumption
81 should be based on knowledge of the disease, the mechanism of action of the drug, on a priori
82 knowledge about ethnic factors and their potential impact on drug response in each region, as well as
83 any data available from early exploratory trials with the new drug. The study is intended to describe
84 and evaluate this treatment effect, acknowledging that some sensitivity of the drug with respect to
85 intrinsic and/or extrinsic factors may be expected in different regions and this should not preclude
86 consideration of MRCTs.

87 Ethnic factors are a major point of consideration when planning MRCTs. They should be identified
88 during the planning stage, and information about them should also be collected and evaluated when
89 conducting MRCTs. In the ICH E5 guideline, and for purposes of the present document, ethnic factors
90 are defined as those factors relating to the intrinsic (e.g.; genetic, physiological) and the extrinsic
91 (e.g.; medical practice, cultural and environmental) characteristics of a population. Based on the
92 understanding of accumulated knowledge about these intrinsic and extrinsic factors, MRCTs should be
93 designed to provide information to support an evaluation of whether the overall treatment effect
94 applies to subjects from participating regions.

95 For purposes of sample size planning and evaluation of consistency of treatment effects across
96 geographic regions, some regions may be pooled at the design stage, if subjects in those regions are
97 thought to be similar enough with respect to intrinsic and/or extrinsic factors relevant to the disease
98 area and/or drug under study. In order to further evaluate consistency of treatment effects
99 consideration could also be given to pooling a subset of the subjects from a particular region with
100 similarly defined subsets from other regions to form a pooled subpopulation whose members share one
101 or more intrinsic or extrinsic factors important for the drug development program. The latter approach
102 may be particularly useful when regulators would like additional data to be available from a relevant
103 subpopulation to allow generalisability to a specific population within their regulatory country or region.
104 Both pooled subpopulations and pooled regions should be specified at the study planning stage and be
105 described in the study protocol. These pooled subpopulations and pooled regions may provide a basis
106 for regulatory decision-making for relevant regulatory authorities.

107 The guiding principle for determining the overall sample size in MRCTs is that the test of the primary
108 hypothesis can be assessed, based on combining data from all regions in the trial. The sample size
109 allocation to regions or pooled regions should be determined such that clinically meaningful differences
110 in treatment effects among regions can be described without substantially increasing the sample size
111 requirements based on the primary hypothesis.

112 In the planning and design of MRCTs, it is important to understand the different regulatory
113 requirements in the concerned regions. Efficient communication among sponsors and regulatory
114 authorities at a global level can facilitate future development of drugs. These discussions are
115 encouraged at the planning stage of MRCTs.

116 Ensuring trial quality is of paramount importance for MRCTs. This will not only ensure the scientific
117 validity of the trial results, but also enable adequate evaluation of the impact of intrinsic and extrinsic
118 factors by applying the same quality standard for trial conduct in all regions. In addition, planning and
119 conducting high quality MRCTs throughout drug development will build up trial infrastructure and
120 capability, which over time will result in a strong environment for efficient global drug development.

121 MRCTs can play an important role in drug development programmes beyond their contribution at the
122 confirmatory stage. For example, exploratory MRCTs can gather scientific data regarding the impact of
123 extrinsic and intrinsic factors on pharmacokinetics and/or pharmacodynamics (PK/PD) and other drug
124 properties, facilitating the planning of confirmatory MRCTs. MRCTs may also serve as the basis for
125 approval in regions not studied at the confirmatory stage through the extrapolation of study results.

126 **2. General recommendations in the planning and design of** 127 **MRCTs**

128 **2.1. Strategy-related issues**

129 **2.1.1. The value of MRCTs in drug development**


130 Historically, drug development focused on regulatory strategies designed for specific regulatory
131 regions. In this model, multiregional clinical trials were particularly useful to enable recruitment of the
132 planned number of study subjects within a reasonable timeframe when either the disease and/or
133 condition was rare (e.g.; enzyme deficiency disorder) or when very large numbers of subjects were
134 required (e.g.; cardiovascular outcome trials). More recently, global regulatory strategies are also used
135 to plan and conduct trials more efficiently to facilitate more rapid availability of drugs to patients
136 worldwide. Proper planning and conduct of MRCT's are critical to this effort.

137 MRCTs allow for an examination of the applicability of a treatment to a diverse population. The intrinsic
138 and extrinsic factors that are believed and/or suspected to impact drug responses can be further
139 evaluated based on data from multiple ethnicities in various regions using a single protocol. For
140 example, effects of genetic differences on metabolic enzymes or the molecular target of a drug can be
141 examined in exploratory and/or confirmatory MRCTs with participation of subjects of different
142 ethnicities across regions. Accumulated knowledge of the impact of ethnic factors and experience with
143 global collaboration in various regions will promote inclusion of additional regions in MRCTs.

144 Even though the primary interest in performing MRCTs is to describe treatment effect based on data
145 from subjects in all regions, some sensitivity to the drug with respect to intrinsic and/or extrinsic
146 factors may be expected in different regions and should not preclude consideration of MRCTs. Even in
147 the case where a drug is very sensitive to one or more of these factors, it may still be possible to
148 conduct MRCTs by excluding some regions or populations. Only in rare cases will single-region studies
149 be justified, such as the case where disease prevalence is unique to a single region (e.g., anti-malarial
150 drugs, vaccines specific to local epidemics, or antibiotics for regional-specific strains).

151 MRCTs can facilitate simultaneous global drug development by reducing the number of clinical trials
152 that need to be conducted separately in each region, thereby avoiding the ethical issue of unnecessary
153 duplication of studies. Although MRCTs require more coordination during the planning stage and
154 possibly increase start-up time, their use can provide a pathway for earlier access to new drugs
155 worldwide.

156 As shown in the illustrative examples in Figure 1, the timing of clinical drug development across
157 different regions can be synchronised by the use of MRCTs, in comparison to local trials conducted
158 independently in each region. MRCTs may therefore increase the possibility of submitting marketing
159 authorisation applications to multiple regulatory authorities in different regions simultaneously.



160

161 **Figure 1.** Time schedules of clinical drug development across regions in independent and global
 162 strategies.

163 **2.1.2. Basic requirements and key considerations**

164 In MRCTs, participating regions should share a unified trial hypothesis with common comparators (see
 165 Section 2.2.8), and a primary endpoint which is considered clinically meaningful in all regions (see
 166 Section 2.2.4). Participating sites should be able to enrol a well-described, well-characterised
 167 population of eligible subjects (see Section 2.2.2), where differences between regions with respect to
 168 disease and population factors, medical practices and other intrinsic or extrinsic factors (ICH E5) are
 169 not expected to substantially impact safety and efficacy results. If major ethnic differences in drug
 170 responses are expected, the magnitude of such differences could be examined in exploratory trials
 171 (e.g., exploratory MRCTs) before the planning and design of confirmatory MRCTs.

172 It is also a basic requirement that all sites participating in MRCTs should meet applicable quality and
 173 regulatory standards. Specifically, MRCTs should be conducted in compliance with ICH E6-GCP
 174 standards in all regions and sites, including making sites available for GCP inspections by relevant
 175 regulatory authorities. Monitoring plans and other quality checks should be pre-specified and
 176 implemented in order to address potential risks to trial integrity. Centralised and risk-based monitoring
 177 may be particularly useful for MRCTs in order to monitor and mitigate the impact of emerging regional
 178 differences in, for example, retention compliance or adverse event reporting (ICH E6 addendum).
 179 Timely and accurate flow of information should occur between the sponsor, trial management team
 180 and participating sites. For example, it is critical that important safety information during a trial is
 181 provided appropriately to all investigational sites in a timely manner (ICH E2) (see Section 2.2.6).

182 To address these basic requirements, it is recommended that investigators and experts representing
 183 participating regions are involved in the planning and design of MRCTs. This facilitates taking into
 184 consideration differences among regions in extrinsic factors such as local medical practices,
 185 administration and interpretation of patient reported outcomes, and endpoint measurements. The
 186 impact of some of these factors may be controlled or mitigated via specified clinical management of
 187 subjects during the trial, and by relevant inclusion and exclusion criteria. It is also important to have
 188 common training for investigators and study personnel in all regions before initiating the trial, in order
 189 to ensure that the trial objectives are met through a standardised implementation of the trial protocol,
 190 and that an appropriate level of data quality is achieved.

191 **2.1.3. Scientific consultation meetings with regulatory authorities**

192 Sponsors of MRCTs are encouraged to have scientific consultation meetings with regulatory authorities.
193 These interactions should take place during the planning stage of MRCTs to discuss the regulatory
194 requirements for the overall development plan and the acceptability of MRCT data to support
195 marketing authorisations. Conducting such consultation meetings early in the planning stage of MRCTs
196 will enable the comments received from regulatory authorities to be taken into consideration. The
197 sponsor should communicate which authorities are providing regulatory advice and how that advice is
198 being taken into consideration in preparing the relevant documents (e.g., the protocol). Inter-authority
199 scientific discussions are encouraged to allow for harmonisation of study requirements.

200 **2.2. Clinical trial design and protocol-related issues**

201 **2.2.1. Pre-consideration of regional variability and its potential impact on** 202 **efficacy and safety**

203 In the planning stage, regional variability and the extent to which it can be explained by intrinsic and
204 extrinsic factors should be carefully considered in determining the role MRCTs can play in the
205 development strategy. The most current and relevant data should be used to understand the potential
206 sources of regional variability. If historical data are used, it should be considered whether these data
207 are still relevant in terms of scientific and methodological validity and with respect to current treatment
208 context.

209 Factors related to the disease such as prevalence, incidence and natural history are expected to vary
210 across regions, as are disease definitions, methods of diagnosis, and the understanding of certain
211 endpoints. These differences should be minimised by precisely defining inclusion and exclusion criteria
212 and study procedures.

213 It is acknowledged that there are almost always small differences in medical practices across regions,
214 and these can be acceptable. However, substantial differences may have a large impact on the study
215 results and/or their interpretation. Common training of investigators and study personnel in all
216 involved regions before initiating the trial may be able to reduce the impact of these differences.

217 Factors, such as distribution of baseline demographics (e.g., body weight or age) may differ between
218 regions, and may potentially impact study results. Additionally, factors such as cultural or socio-
219 economic factors and access to healthcare may impact study results and also recruitment, compliance,
220 and retention, as well as the approaches that could be used to retain subjects. Cultural differences
221 such as use of contraceptives and preferences for a particular route of administration should also be
222 considered.

223 It is recognised that different drugs may be more or less sensitive to regional variability based on
224 intrinsic factors, such as genetic polymorphism of drug metabolism or receptor sensitivity (described in
225 ICH E5 Appendix D) which can impact PK/PD, and efficacy and safety of the drug. This applies not only
226 to the investigational drug, but also to comparators and concomitant medications and should be taken
227 into account during planning of MRCTs.

228 Often, the degree of variability based on the factors mentioned above can be mitigated by proper
229 design and execution of MRCTs. Providing additional support as needed (e.g., logistical, infrastructure,
230 laboratory) to specific regions or other mitigation strategies should be considered and implemented to
231 ensure harmonisation.

232 **2.2.2. Subject selection**

233 In MRCTs, subject selection should be carefully considered to better understand and possibly mitigate
234 potential sources of regional variability and their impact on trial results. Clear and specific inclusion and
235 exclusion criteria that are acceptable and can be applied across all regions should be included in the
236 protocol.

237 To harmonise subject selection, uniform classification and criteria for diagnosis of the disease or
238 definition of the at-risk population should be implemented. When diagnostic tools (e.g., biochemical
239 testing, genetic testing) are needed for the selection of subjects, these should be clearly specified
240 including the degree to which local validated tools and qualified laboratories may be used. In
241 particular, when subject selection is based on subjective criteria (e.g., use of symptom scales in
242 rheumatoid arthritis), the same methods (e.g., validated symptom scales and/or scores in the
243 appropriate language) should be used uniformly across regions. Even so, patient reporting of
244 symptoms may vary by region and may lead to differences in the types of patients included in the
245 trials. This aspect should be considered in the planning stage, in order to implement training
246 requirements and other strategies for potential mitigation of the impact.

247 Recommended tools, such as validated imaging instruments and measurements of biomarkers, should
248 be available, or made available, in all regions when these tools are utilised for subject selection.
249 Methods for specimen collection, handling and storage should be specified to the degree required.
250 Methods of imaging need to be clearly defined and are recommended to be standardised throughout
251 the trial.

252 **2.2.3. Selection of doses for use in confirmatory MRCTs**

253 In order to select the dose for confirmatory MRCTs, it is necessary to execute well-planned
254 development programmes during phase I – II that include PK and/or PK/PD studies of applicable
255 parameters, in order to be able to identify important regional differences which may impact dose
256 selection. If PK and/or PK/PD data are needed from different regions, early phase MRCTs should be
257 considered to efficiently gather such data or to better understand PK/ PD prior to initiating
258 confirmatory MRCTs.

259 When applicable, PK investigations should be undertaken in subjects from major subpopulations that
260 are intended to be included in MRCTs (e.g., Asian, Black and Caucasian). Adequate PK comparisons
261 between subpopulations will allow for decisions with respect to the need for pharmacodynamics studies
262 and dose-response studies in different regions and/or subpopulations. It is encouraged to collect
263 genetic data (e.g., genotypes of metabolising enzymes) from subjects enrolled in the early trials to
264 examine the effects of genetic factors on PK and PD. Such early data may provide useful information
265 when determining optimal dosing regimen(s) for further studies.

266 Population PK approaches and/or model-based approaches (e.g., exposure-response models) may be
267 useful to identify important factors affecting drug responses in different populations, and to set an
268 appropriate dose range for further dose-response studies. Dose response studies should cover a broad
269 range of doses and generally include the subpopulations to be studied in MRCTs. However, it may not
270 be necessary to obtain PK/PD or dose-response data from subjects in all regions planned to be
271 included in confirmatory MRCTs, if important regional differences in PK/PD and dose-response are not
272 anticipated (e.g., the drug is unlikely to be sensitive to intrinsic and extrinsic factors). The acceptability
273 of such a strategy should be discussed in advance with relevant regulatory authorities. If substantial
274 differences are anticipated (e.g., the drug is sensitive to intrinsic and/or extrinsic factors), further
275 investigations may be needed. These could include a dose-response study conducted in a particular

276 region or additional dose-response or PK/PD studies conducted for a broader population that would
277 allow further evaluation of the impact of intrinsic and extrinsic factors on dose-response.

278 The dose regimens in confirmatory MRCTs (based on data from studies mentioned above) should in
279 principle be the same in all participating regions. However, if early trial data show a clearly defined
280 dose/exposure/response relationship that differs for a region, it may be appropriate to use a different
281 dosing regimen in that region, provided that the regimen is expected to produce similar therapeutic
282 effects with an acceptable safety margin, and is fully justified and clearly described in the study
283 protocol.

284 **2.2.4. Choice of endpoints**

285 The general principles for endpoint selection and definitions, which are provided in ICH E9, apply. The
286 aspects of particular importance to MRCTs are described here.

287 ***Primary Endpoint***

288 An ideal study endpoint is one that is clinically meaningful, accepted in medical practice (by regulatory
289 guidance or professional society guidelines) and sufficiently sensitive and specific to detect the
290 anticipated effect of the treatment. For MRCTs, the primary endpoint, whether efficacy or safety,
291 should satisfy these criteria as well as being acceptable to all concerned regulatory authorities to
292 ensure that interpretation of the success or failure of the MRCT is consistent across regions and among
293 regulatory authorities. Agreement on the primary endpoint ensures that the overall sample size and
294 power can be determined for a single (primary) endpoint based on the overall study population and
295 also agreed upon by the regulatory authorities. If, in rare instances, agreement cannot be reached due
296 to well-justified scientific or regulatory reasons, a single protocol should be developed with endpoint-
297 related sub-sections tailored to meet the respective requirements of the regulatory authorities. In this
298 case, since regulatory approvals are based on different primary endpoints by different authorities, no
299 multiplicity adjustment is needed for regulatory decision-making. As stated in ICH E9, the primary
300 endpoint should be relevant to the patient population. In MRCTs, this relevance needs to be considered
301 for all regions in the trial and with respect to the various drug, disease and population characteristics
302 represented in those regions (see Section 2.2.1).

303 MRCTs may introduce the need for further consideration regarding the definition of the primary
304 endpoint. While endpoints like mortality or other directly measurable outcomes are self-explanatory,
305 others may require precise and uniform definitions (e.g., progression-free survival). Of specific concern
306 in MRCTs are those endpoints that could be understood and/or measured differently across regions.
307 Examples are hospitalisation, psychometric scales, assessment of quality of life, and pain scales. To
308 guarantee that such scales can be properly interpreted, the scales should be validated and their
309 applicability to all relevant regions justified before starting the MRCT. Furthermore, it should be
310 ensured that the outcome is relevant to all regions.

311 The primary endpoint of MRCTs should be one for which experience is already available in the
312 participating regions. In cases where prior experience with an endpoint only exists in one or a subset
313 of regions involved in the MRCT, its adoption as primary endpoint will require discussion and
314 agreement with regulatory authorities regarding the basis for the evidence, keeping in mind that the
315 forthcoming trial can add information about clinical relevance of the agreed endpoints.

316 In addition to endpoint selection and definition, regulatory agreement should also be obtained on the
317 timing and methods of the primary endpoint assessment, as discussed in Section 2.2.6.

318 **Secondary Endpoints**

319 Where possible, harmonisation of secondary endpoints is encouraged to maintain the feasibility and
320 improve the quality of trial conduct. However, in some cases, individual regulatory authorities may
321 propose different secondary endpoints relevant to their interests and experience. Even in such cases,
322 all secondary endpoints including those selected only for a particular regulatory authority should be
323 described in the protocol. It is in the interest of the sponsor to describe the specific advantages of the
324 investigational product in terms of secondary endpoints as precisely as possible during the planning
325 stage of MRCTs, to reduce the need for (and impact of) multiplicity adjustments for multiple endpoints,
326 thereby improving the chance for successfully demonstrating the intended effect. Control of the Type I
327 error across both primary and secondary endpoints may be required by some regulatory authorities.

328 **Other Considerations**

329 Although endpoints may not require formal validation, some endpoints may be subject to subtle
330 differences in understanding, when used in different cultural settings. For example, certain types of
331 adverse events may be more sensitively reported (e.g., more frequently) in some regions and not in
332 others, resulting in differences in reporting patterns due to cultural variation rather than true
333 differences in incidence. Use of these variables as endpoints in MRCTs will require careful planning.
334 Approaches to minimise the impact of this variation in data collection and interpretation of the study
335 results should be described and justified in the study protocol.

336 Endpoints that are only of interest for one or a few regions could be considered for a regional sub-trial
337 of the MRCT. However, care should be taken to ensure that ascertainment of regional sub-trial
338 endpoints do not hamper in any way the conduct of the main trial. In particular, consideration should
339 be given to the impact of additional patient burden, and the potential to induce reporting bias with
340 respect to other endpoints in determining whether regional sub-trials can be conducted or whether a
341 separate trial is needed.

342 **2.2.5. Estimation of an overall sample size and allocation to regions**

343 **General considerations and overall sample size**

344 The overall sample-size for MRCTs is determined by a treatment effect that is considered clinically
345 meaningful and relevant to all regions based on knowledge of the disease, the mechanism of action of
346 the drug, on a priori knowledge about ethnic factors and their potential impact on drug response in
347 each region, as well as any data available from early exploratory trials with the new drug. However,
348 the treatment effect may be influenced by intrinsic and/or extrinsic factors that vary across regions.
349 The MRCT should therefore also be designed to provide sufficient information for an evaluation of the
350 extent to which the overall treatment effect applies to subjects from different regions. Only if regional
351 variation is known or suspected a priori to be of such a high degree that the treatment effect will be
352 difficult to interpret, then conducting separate trials in at least some of the regions may be a more
353 appropriate drug development strategy.


354 The ICH E9 provides general principles for determining sample sizes of clinical trials and a detailed
355 description of the factors impacting that determination. The same principles apply to MRCTs. As stated
356 in E9, the overall sample size is usually determined by the primary objective of the trial, stated in
357 terms of study endpoints and specific hypotheses, as well as the size of the treatment effect to be
358 detected, background and/or control group mean values or event rates, variability of the primary
359 outcome, test statistics, Type I error control, multiplicity, and missing data considerations. In addition
360 to these factors, the overall sample size calculation for the MRCT should take into consideration the

361 potential for increased variability due to the inclusion of multiple regions and a possibly more
362 heterogeneous population, compared to a single-region trial. Also with MRCTs, even after attempts at
363 reaching consensus among regional authorities, it may be the case that different regulatory
364 requirements (e.g., regarding the trial's endpoints, subgroup analysis requirements, non-inferiority
365 margins, etc.) will impact the overall sample size.

366 Where the primary objective of MRCTs is to assess non-inferiority (or equivalence) of two drugs, the
367 margin is a critical factor in determining the overall sample size and should be pre-specified in the
368 study protocol. Ideally, the same margin would be acceptable to all regulatory authorities, but if
369 different margins are required for different regulatory regions, the rationale should be provided in the
370 protocol. The protocol should clearly specify which margin is in effect for which region involved in the
371 trial, and the sample size calculation should take into consideration the most stringent margin.

372 **Allocation to Regions**

373 Although knowledge of intrinsic and extrinsic factors accumulates as drug development moves from
374 the exploratory to confirmatory stage (see Section 2.2.1), empirical evidence exists that region is a
375 feasible and valuable indicator for unknown and important differences in intrinsic and/or extrinsic
376 factors, which may exist among populations. Figure 2 illustrates that the primary endpoint may be
377 modulated by known intrinsic and/or extrinsic factors such as disease severity (Figure 2a) or ethnicity
378 (Figure 2b) across regions. Consequently, the treatment effect of the primary endpoint may be
379 influenced by those known factors, along with other potential unknown factors across regions. When
380 these factors have different distributions among the regions, some variation in treatment effect among
381 regions may be observed. Therefore proper planning for sample size allocation to region is needed in
382 order to describe the treatment effect in the multi-regional setting.



383

384 **Figure 2.** Illustration of primary endpoint responses modulated by intrinsic and extrinsic factors
385 across regions; (2a) by severity of disease, (2b) by ethnic group.

386 Understanding the treatment effect in the multi-regional setting is an important objective of MRCTs,
387 and for that purpose, MRCTs are usually stratified by region to reflect the similarity of patients within a
388 region regarding genetics, medical practice, and other intrinsic and extrinsic factors. Without
389 substantially increasing the overall sample size required for the primary hypothesis, the sample size
390 allocation to regions should be determined such that clinically meaningful differences in treatment
391 effects estimated in different regions can be described.

392 There are several approaches that could be considered for allocating the overall sample size to regions
393 each with its own limitations, and a few are described below. One approach is to determine the
394 regional sample sizes needed to be able to show similar trends in treatment effects across regions.
395 Allocating equal numbers of patients to each region would increase the likelihood of showing similar
396 trends; however, such an allocation strategy may not be feasible or efficient in terms of enrolment and

397 trial conduct. Another approach is to determine the sample size needed in one or more regions based
398 on the ability to show that the region-specific treatment effect preserves some pre-specified proportion
399 of the overall treatment effect. This allocation strategy, however, would be difficult if all regions have
400 this requirement. A third approach is to enrol subjects in proportion to region size and disease
401 prevalence without adhering to a fixed allocation strategy for regions. This allocation strategy will likely
402 result in very small sample sizes within some countries and/or regions and therefore be insufficient
403 alone to support any evaluation of consistency among region specific effects. A fourth approach is to
404 determine the regional sample sizes to be able to achieve significant results within one or more
405 regions. This allocation strategy brings into question the reasons for conducting MRCTs and should be
406 discouraged. A fifth approach is to require a fixed minimum number of subjects in one or more regions.
407 Any local safety requirement for minimum number of subjects to be exposed to the drug is generally a
408 programme level consideration and should not be a key determinant of the regional sample size in
409 MRCTs.

410 Because there is no uniformly acceptable or standardised approach to regional sample size allocation, a
411 balanced approach is needed to ensure that the trial is feasible but also provides sufficient information
412 to evaluate the drug in its regional context. Therefore, sample size allocation should take into
413 consideration region size, the commonality of enrolled subjects across regions based on intrinsic and
414 extrinsic factors and patterns of disease prevalence, as well as other logistical considerations to ensure
415 enrolment is able to be completed in a timely fashion.

416 For purposes of sample size planning and evaluation of consistency of treatment effects across regions,
417 some regions may be pooled, if subjects in those regions are thought to be similar with respect to
418 intrinsic and/or extrinsic factors, which are relevant to the disease area and/or drug under study.
419 Consideration could also be given to pooling a subset of the subjects from a particular region with
420 similarly defined subsets from other regions to form a pooled subpopulation whose members share one
421 or more intrinsic or extrinsic factors important for the drug development programme. Use of this
422 pooled subpopulation can further support the evaluation of consistency of treatment effects across
423 regional populations. It should be discussed at the planning stage how the analyses of pooled regions
424 and/or pooled subpopulations may provide a basis for the regulatory decision-making for relevant
425 regulatory authorities. This should also be specified and be described in the study protocol in advance.

426 As an example of a pooled subpopulation; in Figure 2b, an ethnic group B that can largely be enrolled
427 from region I could alternatively be enrolled globally (e.g.; region I and II) to facilitate scientific
428 evaluation of the impact of ethnic factors and regulatory decision making. At the same time the
429 allocation should provide a minimally sufficient amount of information within each region to support
430 assessment of consistency in treatment effects. Examples of pooled subpopulations include Hispanics
431 living in North and South America, or Caucasians living in Europe and North America. Examples of
432 pooled regions include East Asia, Europe, and North America.

433 The above considerations for sample size planning to assess regional variation apply to assessing
434 consistency of treatment effect with respect to other intrinsic and/or extrinsic factors. It may be
435 possible to pool regions or subpopulations in these assessments in order to increase the ability to
436 evaluate consistency.

437 In general, comparing with sample size requirements in regional or local trials, the potential increase of
438 the overall sample size in MRCTs should be due primarily to the increased variability and/or decreased
439 overall treatment effect anticipated for a multi-regional population. Based on accumulated information
440 about intrinsic and/or extrinsic factors, the use of pooled regions and pooled subpopulations may
441 provide practical ways to maintain the total sample size while allowing the descriptions of treatment
442 effect in its regional context. Discussion with regulatory authorities on the proposed sample allocation
443 is highly recommended at the planning stage.

444 In certain situations (e.g.; rare diseases, unmet medical needs), sample size allocation in regions could
445 generally be allowed more flexibility. If prevalence of the disease is substantially different in one or
446 more regions, scientific consultation with the relevant regulatory authority in advance is
447 recommended. Acceptability of the trial should be discussed with the authorities, as recruitment may
448 be heavily skewed towards the more prevalent region, and this may limit the ability to characterise
449 regional differences in safety and efficacy.

450 **2.2.6. Collecting and handling of efficacy and safety information**

451 Collecting and handling methods of efficacy and safety information should be standardised across
452 participating regions. Safety reporting should be conducted in accordance with ICH E2. When local
453 regulations specify different requirements, such as timelines for expedited reporting, these should also
454 be adhered to locally. The specific timeframe for safety reporting should be described in the protocol,
455 and the investigators should be trained appropriately. In the case of MRCTs, important safety
456 information should be handled both with adherence to any local regulations, and also in adherence to
457 ICH E2A. Important safety information should always be provided to the relevant stakeholders (e.g.,
458 investigators, ethics committees) in a timely manner.

459 In MRCTs of long duration, where special concerns have been identified, and/or where operational
460 regions are quite large, the use of a central independent data monitoring committee (with
461 representation from major regions, as applicable) should be considered, in order to monitor the
462 accumulating efficacy and/or safety information from the MRCT. If adjudication of endpoints and/or
463 events is planned, a centralised assessment by a single adjudication committee should be considered.

464 Endpoint ascertainment should also be harmonised as far as possible (see Section 2.2.4). If subjective
465 endpoints are used, coordinated training of investigators and clinical site personnel is particularly
466 important for the handling of data in a standardised manner. If laboratory data are used in key primary
467 and secondary endpoints, centralised laboratory tests should be considered.

468 Coordinated site initiation is particularly important in MRCTs to ensure proper conduct, completion and
469 reporting of results without any delays among regions. To comply with the quality management
470 described in ICH E6, the sponsor should implement a system to manage quality throughout the design,
471 conduct, evaluation, reporting and archiving of MRCTs. It could be considered to use electronic data
472 capturing and reporting, to gather information and data (including relevant ethnic factors) from all
473 regions in a standardised way without delays. If a case report form and other related documents are
474 translated to the local language, consistency of documents between languages should be ensured.

475 **2.2.7. Statistical analysis planning to address Specific features of MRCTs**

476 ICH E9 provides general statistical principles for planning and conducting statistical analyses of
477 randomised clinical trials. Aspects of analysis planning that are particularly important for MRCTs are
478 described below.

479 ***Obtaining Regulatory Input on Analysis Strategy***

480 It is recommended to have early discussions with the different regulatory authorities involved in the
481 MRCT, and to obtain their agreement with the proposed analysis strategy. The standard is to specify a
482 single primary analysis approach in the statistical section of the study concept to be agreed upon with
483 the authorities in advance of starting the trial. If different analysis strategies are required by different
484 authorities for well-justified scientific or regulatory reasons, they should be described in the trial
485 protocol. If, in addition, a statistical analysis plan is developed as a separate document for the MRCT, a
486 single comprehensive analysis plan describing the analytical approaches to be used to meet the

487 different regulatory requirements should be developed. For blinded studies, the statistical analysis plan
488 should be finalised prior to unblinding of treatment assignments (at interim or final report) and
489 submitted to regulatory agencies upon request.

490 ***Evaluation of Subgroups Defined by Intrinsic and Extrinsic Factors***

491 To investigate observed differences in treatment effects among regions, which may be due to
492 differences in intrinsic and/or extrinsic factors, it is recommended that subgroup analyses be planned
493 during the design stage and pre-specified in the protocol and statistical analysis plan. Of most interest
494 are subgroups defined according to intrinsic and extrinsic factors likely to be prognostic for the course
495 of the disease or plausibly predictive of differential response to treatment. Examples include subgroups
496 defined by disease stage (e.g., mild, moderate, or severe), race and/or ethnicity (e.g., Asian, Black or
497 Caucasian), medical practice/therapeutic approach (e.g., different doses used in clinical practice) or
498 genetic factors (e.g., polymorphisms of drug metabolising enzymes), that are well-established for the
499 disease or therapy and suggested from early stages of investigation.

500 Well-reasoned and prospective planning of the analysis of the impact of intrinsic and extrinsic factors
501 on treatment effects can potentially minimise the need for data-driven investigations of subgroup
502 findings and can establish a good foundation for evaluating the consistency of region specific treatment
503 effects. Furthermore, pre-specified subgroup analyses for relevant study subpopulations that are
504 defined beyond geographical boundaries and based on common intrinsic and /or extrinsic factors may
505 be useful for generating key scientific evidence to support regional or national marketing authorisation.

506 The statistical analysis section of the protocol should describe the analytical approach for assessment
507 of subgroup differences. In addition to summarising the key efficacy and safety endpoints by subgroup,
508 model-based analyses can be useful to assess consistency of treatment effects with respect to one or
509 more subgroup factors. Forest plots or other graphical methods that depict treatment effects for a
510 series of subgroups may also be useful in assessing consistency of subgroup-specific treatment effects.

511 ***Considering regions in the primary analysis***

512 If randomisation is stratified by region, then following the ICH E9 principle, the primary efficacy
513 analysis designed to test hypotheses about the overall treatment effects should adjust for regions
514 using appropriate statistical methods. If some regions were combined based on intrinsic and/or
515 extrinsic factors, then the pooled regions would be used as stratification factors in the primary
516 analysis. The appropriate strategy for subgroup analyses is to follow the primary analysis model of the
517 trial, including stratification by region.

518 ***Examination of regional consistency***

519 The statistical analysis plan should include a strategy for evaluating consistency of treatment effects
520 across regions, and for evaluating how any observed differences across regions may be explained by
521 intrinsic and/or extrinsic factors. Various analytical approaches to this evaluation, possibly used in
522 combination, include but are not limited to (1) descriptive summaries, (2) graphical displays (e.g.,
523 Forest plots, funnel plots), (3) model-based estimation including covariate-adjusted analysis, and (4)
524 test of treatment by region interaction, although it is recognised that such tests often have very low
525 power. The assessment of the consistency of treatment effects across regions, considering the
526 plausibility of the findings, should be done with diligence before concluding that potential differences
527 between treatment effects in regions are a chance finding.

528 If subgroup differences (e.g., by gender) in treatment effects are observed, then an examination of
529 whether the subgroup differences are consistent across regions or pooled regions is recommended. In

530 general, the credibility of subgroup and/or regional findings should also take into consideration
531 biological plausibility, consistency (internal and/or external) of findings, the strength of evidence, as
532 well as the statistical uncertainty. The analyses and evaluation of treatment effects should be planned
533 to enable the qualitative and/or quantitative evaluation of benefit/risk across subgroups and across
534 regions.

535 ***Estimation of regional treatment effects***

536 The statistical analysis section of the protocol should describe appropriate statistical methods for
537 estimating and reporting treatment effects and associated measures of variance for individual regions,
538 if sample sizes allow. The same analysis strategy should be used as planned for the primary analysis.
539 This plan should include a determination of the adequacy of sample sizes to support accurate
540 estimation within each region or pooled region for which reporting of treatment effect is of interest. If
541 the sample size in a region is so small that the estimates of effect are unreliable, the use of other
542 methods should be considered, including the search for options to pool regions based on
543 commonalities, or borrowing information from other regions or pooled regions using an appropriate
544 statistical model.

545 ***Monitoring and mitigation of MRCT conduct***

546 Centralised and risk-based monitoring may be particularly useful for MRCTs to identify variability
547 across regions and sites in protocol compliance, e.g., differences in follow-up, compliance with study
548 medications, adverse event reporting, and/or extent of missing data. Mitigation approaches should
549 take regional differences into consideration.

550 **2.2.8. Selection of comparators**

551 The choice of control groups should be considered in the context of the available standard therapies,
552 the adequacy of the evidence to support the chosen design, and ethical considerations. Comparators in
553 MRCTs should in principle be the same in all participating regions. Due to the complexity in setting up
554 MRCTs, some keypoints are addressed in the following paragraphs, focusing on practical and ethical
555 issues associated with the use of comparators:

- 556 • Appropriateness of the choice of comparators should be justified based on scientific and other
557 relevant information, including international treatment guidelines.
- 558 • Active controls should in principle be dosed and administered in the same way in all regions. If the
559 approved doses of active comparators are different among regions, the impact of such difference
560 on analysis and evaluation of data should be considered, and relevant scientific reasons, such as
561 different drug exposure induced by intrinsic factors, should be justified in the protocol.
- 562 • The same dosage form (e.g., capsules vs tablets) for active comparators should generally be used
563 among regions participating in MRCTs to ensure consistency of treatment effects. Different dosage
564 forms can cause problems for maintenance of the blinding and data interpretability. Unless the
565 effect of the different dosage forms on the dissolution profiles, bioavailability and blinding are well-
566 characterised and negligible the same dosage form should be used.
- 567 • In order to ensure the quality of the investigational drugs, it is recommended to use the same
568 source of the active comparators in all participating regions. When active comparators from
569 different sources are used in MRCTs, justification should be provided, such as bioequivalence data,
570 to support the differently sourced comparators.

- 571 • The product information used in the region where the product is sourced should be used
572 consistently in all participating regions. If the sourced product information differs from local
573 product information, this should be explained in the protocol and the informed consent form (e.g.,
574 there may be differences in the adverse event reporting and/or display between the package
575 inserts).

576 In addition, active comparators in MRCTs should ideally be approved in all participating regions.
577 However, there could be situations where active comparators used in MRCTs are not approved or not
578 available in specific regions, but have been approved and available in some ICH regions. Therefore the
579 appropriateness of the selected control(s) may vary between the regions. The reason for the use of an
580 unapproved drug vs the current standard of the region should therefore be described in the protocol
581 based on scientific information, such as a guideline and other relevant documents, to justify the choice
582 of comparator. Development status of the unapproved drug in the region should also be described in
583 the protocol. Pre-consideration is also necessary regarding how such an unapproved drug may affect
584 subjects in the region, especially regarding safety. A plan for how to address the issue of non-approved
585 control treatment(s) should be explained in the protocol. In these circumstances, design of MRCTs
586 should involve consultation with the relevant regulatory authorities to determine the appropriateness
587 of such trial designs as part of the overall drug approval strategy.

588 **2.2.9. Handling concomitant medications**

589 In general, drugs not allowed in the protocol should be the same throughout the regions to the extent
590 possible, but there may be some differences in the drugs actually used due to different medical
591 practices. This could be acceptable if not expected to substantially impact results.

592 Concomitant medications may be required as an important part of the treatment. In circumstances
593 where approved drugs are combined with an investigational drug (e.g., a combination regimen of
594 anticancer drugs) the same dosage regimen in all regions should generally be applied. If required by
595 protocol, concomitant medications that are not approved in a region should have their use justified
596 based on scientific information, treatment guidelines and other relevant documents. This could include
597 documentation that the concomitant medication is approved in at least one of the participating regions.
598 It should be allowed to use an unapproved concomitant drug; however the impact of using the
599 unapproved drug vs the approved standard in the relevant regions should be discussed with regulatory
600 authorities and described in the protocol (see section 2.2.8). The medication will need to be supplied in
601 regions in which it is otherwise not available.

602 For concomitant medications that are not required by protocol, classes of medications that are not
603 allowed during the study should be identified. The effects of differences in concomitant medications on
604 drug responses should be considered in advance. Changes in dosage of concomitant medications that
605 may impact the study endpoints should be carefully documented within each subject and explained
606 throughout the trial period as specified in the protocol.

607 To ensure a subject's condition is stable before starting the investigational drug, a prior observation
608 period may be useful for control of some concomitant medications. Changes in concomitant
609 medications or doses of medications that may be expected to impact the study endpoints during the
610 trial may be allowed, based on pre-specified criteria. If a major impact on drug responses is expected,
611 based on differences in concomitant medications, additional measures to minimise impact should be
612 considered, such as additional PK or subgroup analyses.

613 **3. Glossary**

- 614 • Regulatory region:

615 A region for which a common set of regulatory requirements applies for drug approval (e.g.,
616 European Union, Japan).

- 617 • Pooled regions:

618 A subset of enrolled subjects where data can be pooled together within and/or across geographical
619 regions, countries or regulatory regions based on a commonality of intrinsic and/or extrinsic factors
620 for purpose of regulatory decision-making.